General
Preferred name
Darolutamide
Synonyms
BAY-1841788 ()
ODM-201 ()
Darolutamide (ODM-201) ()
Nubeqa ()
BAY1841788 ()
BAY 1841788 ()
P&D ID
PD021518
CAS
1297538-32-9
Tags
available
drug
Drug Status
investigational
approved
Drug indication
Prostate cancer
Max Phase
Phase 4
First approval
2019
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Darolutamide is a nonsteroidal, potent and selective antagonist of the androgen receptor (antiandrogen) . It is able to overcome resistance to current nonsteroidal androgen receptor-targeted therapies ( and ). Darolutamide was developed by Orion and Bayer HealthCare.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
14
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
398.13
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
2.67
TPSA
119.62
Fraction CSP3
0.26
Chiral centers
2.0
Largest ring
6.0
QED
0.59
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Endocrinology/Hormones
Vitamin D Related/Nuclear Receptor
Target
Androgen Receptor
Source data
